In the end of January, investors and companies from the Umeå region met with Scandinavian and international representatives for partnering meetings.
On January 30, Biotech Umeå Investment Day took place at Grand Hôtel in Stockholm. The day started with partnering sessions between companies from the Umeå region and investors and business angels from Scandinavia and abroad – in total, over 58 partnering meetings took place during three hours. All companies from Umeå also delivered a two-minute pitch in front of the whole audience of investors. In the afternoon, more investors and other guests arrived to participate in the afternoon program, which attracted a total of 85 people.
The afternoon program contained an mix of presentations. Torbjörn Bäckström, CEO of the Umecrine group, talked about their strategy to finance several paralell drug development projects in the CNS area. They are currently concluding a phase II study in one of their companies, Umecrine Mood. Claire Ingram from Stockholm School of Economics explained what crowd-funding is all about and gave examples of how it has been and could be used in the life science sector. Also, Gunnar Pohl, the founder and CEO of Nordic Biomarker, gave a presentation about how his company’s journey from the incubator to Deloitte’s Technology Fast 50 list in November last year.
Biotech Umeå Investment Day was arranged by Biotech Umeå in cooperation with Connect Norr, Umeå Biotech Incubator, Uminova Invest, Almi Innovationsbron, Västerbotten Investment Agency and Uminova Innovation. The event was sponsored by PwC and Norrlandsfonden.
Photo: Anna Gustafsson -SEB Venture Capital, Hedvig Andersén – Industrifonden, Jennie Ekbeck – CEO Umeå Biotech Incubator
Source: Biotech Umeå